Corcept Therapeutics Incorporated provided earnings guidance for the full year of 2022. For the period, the company expects revenue to be in the range of $400 million and $430 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
30.94 USD | -1.87% | +11.75% | -4.22% |
May. 28 | Sector Update: Health Care Stocks Retreat Tuesday Afternoon | MT |
May. 28 | Corcept Therapeutics Says Phase 3 Hypercortisolism Trial Meets Primary Endpoint; Shares Advance | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.22% | 3.28B | |
+40.13% | 731B | |
+31.34% | 586B | |
-7.63% | 348B | |
+16.36% | 319B | |
+0.31% | 273B | |
+13.58% | 235B | |
-6.67% | 203B | |
+7.47% | 202B | |
+3.18% | 159B |
- Stock Market
- Equities
- CORT Stock
- News Corcept Therapeutics Incorporated
- Corcept Therapeutics Incorporated Provides Earnings Guidance for the Full Year of 2022